Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Chronic HCV Genotype 4 Infection Without Cirrhosis and With Compensated Cirrhosis in Egypt (AGATE-II)

Conference Reports for NATAP

66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015


Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Chronic HCV Genotype 4 Infection Without Cirrhosis and With Compensated Cirrhosis in Egypt (AGATE-II)

	Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco, CA Gamal Esmat1, Wahid Doss2, Roula B Qaqish3, Imam Waked4, Gamal Shiha5, Ayman Yosry2, Mohamed Hassany2, Jennifer King3, Carolyn Setze3, Rebecca Redman3, Niloufar Mobashery3 1Cairo University, Cairo, Egypt; 2National Hepatology & Tropical Medicine Research Insti tute, Cairo, Egypt; 3AbbVie Inc., North Chicago, Illinois, United States; 4National Liver Institute, Menoufiya, Egypt; 5Egyptian Liver Research Institute And Hospital (ELRIAH), Dakahliah, Egypt